KMID : 1134120090120030156
|
|
Journal of Breast Cancer 2009 Volume.12 No. 3 p.156 ~ p.162
|
|
The Clinical Significance of the Estrogen Receptor ¥âExpression for Endocrine Therapy in Patients with ER¥á-negative and Progesterone Receptor-positive Breast Carcinoma
|
|
Park Min-Ho
Ryu Hee-Seon Ro Hye-Won Cho Jin-Seong Yoon Jung-Han Jegal Young-Jong Kim Jo-Heon Lee Ji-Shin Park Chang-Soo
|
|
Abstract
|
|
|
Purpose: Estrogen receptor (ER) is the key therapeutic target in breast cancer. ER¥âhas recently been identified to be distinct from ER¥á. In contrast to ER¥á, the functions of ER¥âin breast cancer are still unclear. We sought to determine whether the expression of ER¥âcan be used as a predictive marker for endocrine therapy for patients with ER¥á- negative breast cancer.
Methods: Formalin-fixed, paraffinembedded tumor specimens from 52 patients with ER-/PR+ invasive breast cancer were immunostained for their ER¥â expression. These patients were treated with adjuvant tamoxifen. The results were correlated with various clinicopathological variables and the follow-up data. The expressions of p53 and HER-2/neu were also analyzed and correlated with the ER¥âstatus.
Results: An ER¥âexpression was observed in 53.8% (28/52) of the breast cancer samples. There was no correlation between the ER¥âexpression and the other clinicopathologic factors (age, tumor size, histologic type, nodal status, histological grade, stage, therapeutic modality, progesterone receptor (PR) expression, p53 expression and HER-2/neu expression). Recurrence was present in 7.7% (2/26) of the patients whose tumors had an ER¥âexpression, as compared to the presence of recurrence in 36.4% (8/22) of the patients whose tumors had no ER¥âexpression (p< 0.05). The patients with ER¥ânegative-tumors revealed lower disease free survival rate than those with ER¥âpositive-tumors (p<0.05). Of the 52 patients, 10 (19.2%) were p53 positive, and 11 (21.2%) were HER-2/neu positive. No significant correlations were observed between ER¥âand p53 or HER-2/ neu.
Conclusion: These results suggest that ER¥âmight be a predictive marker of a response to endocrine therapy in patients with ER-/PR+ invasive breast cancer, although this needs to be confirmed by additional studies.
|
|
KEYWORD
|
|
Breast neoplasms, Endocrine therapy, Estrogen receptor ¥â
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|
|